InvestorsObserver
×
News Home

Is Zentalis Pharmaceuticals Inc (ZNTL) a Winner in the Healthcare Sector?

Thursday, May 19, 2022 10:55 AM | InvestorsObserver Analysts

Mentioned in this article

Is Zentalis Pharmaceuticals Inc (ZNTL) a Winner in the Healthcare Sector?

The 73 rating InvestorsObserver gives to Zentalis Pharmaceuticals Inc (ZNTL) stock puts it near the top of the Healthcare sector. In addition to scoring higher than 72 percent of stocks in the Healthcare sector, ZNTL’s 73 overall rating means the stock scores better than 73 of all stocks.

Overall Score - 73
ZNTL has an Overall Score of 73. Find out what this means to you and get the rest of the rankings on ZNTL!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Zentalis Pharmaceuticals Inc Stock Today?

Zentalis Pharmaceuticals Inc (ZNTL) stock is trading at $22.97 as of 10:53 AM on Thursday, May 19, a loss of -$1.10, or -4.59% from the previous closing price of $24.07. The stock has traded between $22.25 and $24.69 so far today. Volume today is light. So far 134,028 shares have traded compared to average volume of 1,180,519 shares. Click Here to get the full Stock Report for Zentalis Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App